Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Thomas Weisel Ups Array Biopharma to 'Peer Perform'

Thomas Weisel upgraded Array Biopharma (ARRY) to peer perform.

Array and Genentech will advance their oncology programs. Analyst Paul Knight says he upgraded Array from underperform on increased confidence in its drug-development program and recent collaboration announcements.

He thinks Array's agreement with AstraZeneca to develop its lead oncology drug program is a significant milestone in Array's transition, and helps to validate the company's Discovery Platform as a viable means of discovering orally active drug candidates. In the agreement with Genentech, Array will receive an upfront payment and research funding, with the potential to receive development milestones and royalties on resulting product sales.

blog comments powered by Disqus